NO20053125L - Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere. - Google Patents
Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere.Info
- Publication number
- NO20053125L NO20053125L NO20053125A NO20053125A NO20053125L NO 20053125 L NO20053125 L NO 20053125L NO 20053125 A NO20053125 A NO 20053125A NO 20053125 A NO20053125 A NO 20053125A NO 20053125 L NO20053125 L NO 20053125L
- Authority
- NO
- Norway
- Prior art keywords
- smallpox
- recombinant
- seq
- ati
- virus
- Prior art date
Links
- 241000700647 Variola virus Species 0.000 title 2
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000003740 cowpox Diseases 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201814 | 2002-11-25 | ||
| PCT/EP2003/012610 WO2004048582A2 (fr) | 2002-11-25 | 2003-11-12 | Poxvirus de recombinaison comprenant au moins deux promoteurs ati de la vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053125D0 NO20053125D0 (no) | 2005-06-24 |
| NO20053125L true NO20053125L (no) | 2005-06-24 |
Family
ID=32337938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053125A NO20053125L (no) | 2002-11-25 | 2005-06-24 | Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7300658B2 (fr) |
| EP (1) | EP1567653B1 (fr) |
| JP (1) | JP2006515170A (fr) |
| KR (1) | KR20050083839A (fr) |
| CN (1) | CN1717488A (fr) |
| AT (1) | ATE365220T1 (fr) |
| AU (1) | AU2003293675B2 (fr) |
| CA (1) | CA2501168A1 (fr) |
| CY (1) | CY1106883T1 (fr) |
| DE (1) | DE60314541T2 (fr) |
| DK (1) | DK1567653T3 (fr) |
| EA (1) | EA012723B1 (fr) |
| ES (1) | ES2288634T3 (fr) |
| IL (1) | IL167844A (fr) |
| MX (1) | MXPA05005549A (fr) |
| NO (1) | NO20053125L (fr) |
| NZ (1) | NZ540156A (fr) |
| PL (1) | PL375740A1 (fr) |
| PT (1) | PT1567653E (fr) |
| UA (1) | UA85379C2 (fr) |
| WO (1) | WO2004048582A2 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA76731C2 (uk) * | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| ATE315660T1 (de) * | 2002-05-16 | 2006-02-15 | Bavarian Nordic As | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| EP2097517B1 (fr) | 2006-10-16 | 2014-06-04 | Genelux Corporation | Virus recombinant de la vaccine de souche Lister codant pour un anticorps anti-VEGF à chaîne unique |
| EP2303322A1 (fr) * | 2008-06-20 | 2011-04-06 | Bavarian Nordic A/S | Vaccin anti-rougeole à base du virus de la vaccine modifié recombinant |
| DK2352834T3 (en) * | 2008-11-21 | 2017-03-13 | Bavarian Nordic As | VECTOR INCLUDING MULTIPLE HOMOLOGICAL NUCLEOTIDE SEQUENCES |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| WO2013115884A2 (fr) * | 2011-11-15 | 2013-08-08 | Trustees Of Boston University | Inhibiteurs de virus, de type pyridopyrimidinone |
| US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| KR20160140075A (ko) | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| EP3380605A1 (fr) * | 2015-11-24 | 2018-10-03 | GlaxoSmithKline Intellectual Property Development Limited | Procédé de transfection transitoire pour la production de rétrovirus |
| JP7098521B2 (ja) * | 2015-11-24 | 2022-07-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | レトロウイルス産生のための安定な細胞株 |
| WO2017120577A1 (fr) | 2016-01-08 | 2017-07-13 | Geovax Inc. | Compostions et procédés pour générer une réponse immune à un antigène associé à une tumeur |
| WO2017136419A1 (fr) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions et procédés de génération d'une réponse immunitaire à un flavivirus |
| KR20230113832A (ko) * | 2016-08-09 | 2023-08-01 | 시티 오브 호프 | 키메라 폭스바이러스 조성물 및 이의 용도 |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| EP4103231A4 (fr) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | Vaccins et leurs utilisations pour induire une réponse immunitaire contre sras-cov2 |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443964A (en) * | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US5759841A (en) * | 1990-11-20 | 1998-06-02 | Virogenetics Corporation | Immunological composition of measles virus utilizing recombinant poxvirus |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| MY150893A (en) * | 1996-09-24 | 2014-03-14 | Bavarian Nordic As | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
| JP5639736B2 (ja) * | 1999-05-28 | 2014-12-10 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） | ポックスウイルスゲノムへの異種遺伝子の組込みのためのベクター |
| MXPA03001680A (es) | 2000-08-29 | 2004-11-01 | Wyeth Corp | Empaque de particulas de un replicon del virus de acido ribonucleico (arn) de hebra positiva. |
-
2003
- 2003-11-12 CA CA002501168A patent/CA2501168A1/fr not_active Abandoned
- 2003-11-12 MX MXPA05005549A patent/MXPA05005549A/es active IP Right Grant
- 2003-11-12 US US10/535,371 patent/US7300658B2/en not_active Expired - Fee Related
- 2003-11-12 ES ES03789029T patent/ES2288634T3/es not_active Expired - Lifetime
- 2003-11-12 DK DK03789029T patent/DK1567653T3/da active
- 2003-11-12 WO PCT/EP2003/012610 patent/WO2004048582A2/fr not_active Ceased
- 2003-11-12 UA UAA200506292A patent/UA85379C2/ru unknown
- 2003-11-12 JP JP2004554335A patent/JP2006515170A/ja active Pending
- 2003-11-12 AU AU2003293675A patent/AU2003293675B2/en not_active Ceased
- 2003-11-12 PL PL03375740A patent/PL375740A1/xx not_active Application Discontinuation
- 2003-11-12 EP EP03789029A patent/EP1567653B1/fr not_active Expired - Lifetime
- 2003-11-12 AT AT03789029T patent/ATE365220T1/de active
- 2003-11-12 NZ NZ540156A patent/NZ540156A/en not_active IP Right Cessation
- 2003-11-12 KR KR1020057007295A patent/KR20050083839A/ko not_active Abandoned
- 2003-11-12 DE DE60314541T patent/DE60314541T2/de not_active Expired - Lifetime
- 2003-11-12 CN CNA2003801040985A patent/CN1717488A/zh active Pending
- 2003-11-12 EA EA200500879A patent/EA012723B1/ru not_active IP Right Cessation
- 2003-11-12 PT PT03789029T patent/PT1567653E/pt unknown
-
2005
- 2005-04-04 IL IL167844A patent/IL167844A/en not_active IP Right Cessation
- 2005-06-24 NO NO20053125A patent/NO20053125L/no not_active Application Discontinuation
-
2007
- 2007-09-20 CY CY20071101220T patent/CY1106883T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE365220T1 (de) | 2007-07-15 |
| AU2003293675A1 (en) | 2004-06-18 |
| CY1106883T1 (el) | 2012-09-26 |
| DE60314541T2 (de) | 2008-02-28 |
| ES2288634T3 (es) | 2008-01-16 |
| IL167844A (en) | 2011-03-31 |
| EP1567653A2 (fr) | 2005-08-31 |
| JP2006515170A (ja) | 2006-05-25 |
| CN1717488A (zh) | 2006-01-04 |
| EA012723B1 (ru) | 2009-12-30 |
| EP1567653B1 (fr) | 2007-06-20 |
| PT1567653E (pt) | 2007-10-01 |
| DE60314541D1 (de) | 2007-08-02 |
| AU2003293675B2 (en) | 2009-04-23 |
| NZ540156A (en) | 2006-11-30 |
| NO20053125D0 (no) | 2005-06-24 |
| EA200500879A1 (ru) | 2005-10-27 |
| WO2004048582A2 (fr) | 2004-06-10 |
| KR20050083839A (ko) | 2005-08-26 |
| PL375740A1 (en) | 2005-12-12 |
| DK1567653T3 (da) | 2007-10-15 |
| MXPA05005549A (es) | 2005-08-16 |
| UA85379C2 (ru) | 2009-01-26 |
| US20060153874A1 (en) | 2006-07-13 |
| US7300658B2 (en) | 2007-11-27 |
| CA2501168A1 (fr) | 2004-06-10 |
| WO2004048582A3 (fr) | 2004-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106883T1 (el) | Ανασυνδυασμενος ιος ευλογιας που περιεχει τουλαχιστον δυο υποκινητες ατι ιου ευλογιας αγελαδας. | |
| ES2800623T3 (es) | Promotor PR13.5 para respuestas contundentes de células T y anticuerpos | |
| RU98101904A (ru) | Рекомбинантный вирус mva и его использование | |
| US6869793B2 (en) | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines | |
| IL204539A (en) | Foxvirus virus containing defective genes and a losing gene | |
| KR20040108798A (ko) | 변형 백시니아 바이러스 안카라(ｍｖａ)의 게놈내삽입부위로서의 유전자내 영역 | |
| US11286500B2 (en) | Recombinant Orf virus vector | |
| MXPA02011545A (es) | Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| JP5952112B2 (ja) | ポックスウイルスまたは他の感染性因子に対する免疫の急速な誘導に改変ポックスウイルスを使用する方法 | |
| IL164179A0 (en) | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter | |
| UA84667C2 (ru) | Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека | |
| CA2372709A1 (fr) | Vecteur d'integration de sequences heterologues dans des genomes de poxvirus | |
| CA2430115A1 (fr) | Systemes d'expression de virus rsv de recombinaison et vaccins | |
| DE60117053D1 (de) | Herstellung rekombinanter künstlicher hefe-chromosome, welche das genom des humanen cytomegalovirus enthalten | |
| CN101142319B (zh) | 基于使用修饰安卡拉痘苗病毒的疫苗 | |
| NZ512341A (en) | Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments | |
| JP2009232836A5 (fr) | ||
| CA2562136A1 (fr) | Nouveau virus de la bursite infectieuse et vaccin contenant le virus | |
| BR0316553A (pt) | Poxvìrus recombinante que compreende pelo menos dois promotores ati de varìola bovina | |
| CA2351010A1 (fr) | Vaccin a large spectre d'efficacite contre le virus de la bursite infectieuse | |
| DK200201813A (da) | Ekspression af gener i modificeret vaccinia virus ankara ved brug af ATI promotoren fra ko-kopper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |